title: [Psychometric characteristics of the psychotropic-related sexual dysfunction questionnaire. Spanish work group for the study of psychotropic-related sexual dysfunctions].
abstract: BACKGROUND
  The presence of sexual function impairment in patients with psychiatric disorders is very common and could be an effect of the medication (mainly antidepressant and neuroleptics). The patient frequently has difficulties to communicate this adverse effect and the assessment of these changes by the physician should be encouraged. The real SD incidence is underestimated and the use of a specific questionnaire is needed.
  
  
  METHODS
  The authors analyse psychometric characteristics of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ) that includes questions about libido, orgasm, ejaculation, erectile function and general sexual satisfaction. The questionnaire was applied to 62 patients who were taking nefazodone "de novo" (n = 18) or were switched to nefazodone (n = 44) due to bad tolerated sexual dysfunction secondary to other antidepressant.
  
  
  RESULTS
  The PRSexDQ has shown an excellent feasibility with nil percentage of patients with missing responses on all items except on items 1 and 2 (1.7% and 15.5% of patients with missing response). Cronbach's alpha value was 0.93, which indicates adequate reliability. The PRSexDQ also showed adequate construct validity. As it may be expected, the PRSexDQ showed a high correlation with a Clinical Global Impression scores on Sexual Dysfunction (r = 0.79) and moderate correlation with Hamilton Depression scores (r = 0.63). PRSexDQ also showed good discrimination between naive and pretreated depressed or dysthymic patients, with statistically significant differences between those groups of patients. Finally, the instrument showed adequate sensitivity for detecting clinical changes on sexual dysfunction with greater changes in the patients treated previously with antidepressants and who were switched to nefazodone than in naive patients (SES = -3.77 in patients switching to nefazodone; SES = -0.64 in naive patients).
authors.affiliation: Hospital Universitario de Salamanca, Facultad de Medicina, Universidad de Salamanca. angelluis.montejo@globalmed.es
authors.forename: A L
authors.initials: AL
authors.lastname: Montejo
authors.forename: M
authors.initials: M
authors.lastname: García
authors.forename: M
authors.initials: M
authors.lastname: Espada
authors.forename: F
authors.initials: F
authors.lastname: Rico-Villademoros
authors.forename: G
authors.initials: G
authors.lastname: Llorca
authors.forename: J A
authors.initials: JA
authors.lastname: Izquierdo
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects*; D003866:Depressive Disorder / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D010879:Piperazines; D011594:Psychometrics / Q000706:statistics & numerical data; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced* / Q000175:diagnosis*; D011795:Surveys and Questionnaires; D014230:Triazoles / Q000009:adverse effects*
chemical_list: D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone